Document Detail


Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
MedLine Citation:
PMID:  18786009     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
von Willebrand disease (VWD) is a heterogeneous bleeding disorder with symptoms in affected patients ranging from mild effects to potentially devastating haemorrhagic events. Desmopressin (DDAVP) and von Willebrand factor/factor VIII (VWF/FVIII) concentrates are the principal treatments. Haemate P/Humate-P is an intermediate-purity VWF/FVIII concentrate with extensive clinical experience in VWD. This concentrate has been shown to correct haemostatic defects of VWD, with efficacy ratings of good/excellent in nearly all patients treated for bleeding or surgical events. Haemate P/Humate-P has a high content of the high molecular weight (HMW) VWF multimer fraction, which has been shown to be very effective in achieving haemostasis. The HMW VWF multimer pattern in Haemate P/Humate-P is more similar to that of normal human plasma (94% for Haemate P/Humate-P vs. 100% for normal human plasma) than that of other VWF/FVIII concentrates and correlates with functional VWF activities including ristocetin cofactor activity (VWF:RCo) and collagen-binding activity. The recommended dosing of Haemate P/Humate-P is based preferentially on VWF:RCo activity, which is approximately twice that of FVIII:C (2.4:1). Haemate P/Humate-P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades of clinical use. While DDAVP is effective in a large proportion of VWD patients, it may not provide adequate haemostasis in all situations. In such cases, Haemate P/Humate-P is an effective replacement concentrate for all types of VWD in both adult and paediatric patients.
Authors:
G Auerswald; W Kreuz
Related Documents :
18773229 - Cardiovascular complications of cocaine: imaging findings.
1894719 - Cocaine heart disease.
9890389 - Effect of cocaine on cardiac biochemical functions.
4025559 - Responses of the atrial myocardium to cardiac sympathetic nerve stimulation.
3494049 - Recurrent myocardial infarction associated with cocaine abuse in a young man with norma...
20573079 - Putting cocaine use and cocaine-associated cardiac arrhythmias into epidemiological and...
19113799 - High-impact articles related to the management of heart failure: 2008 update.
11078229 - Benefit of coronary reperfusion before intervention on outcomes after primary angioplas...
1424909 - Dynamic left ventricular outflow obstruction related to atrial fibrillation.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  14 Suppl 5     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-09-12     Completed Date:  2008-12-05     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  39-46     Citation Subset:  IM    
Affiliation:
Center for Thrombosis- and Haemostasis, Prof.-Hess-Kinderklinik, Klinikum Bremen-Mitte, Bremen, Germany. guenterauerswald@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Coagulants / adverse effects,  therapeutic use*
Drug Combinations
Factor VIII / adverse effects,  therapeutic use*
Female
Humans
Treatment Outcome
von Willebrand Diseases / drug therapy*
von Willebrand Factor / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Coagulants; 0/Drug Combinations; 0/von Willebrand Factor; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diagnosis of von Willebrand disease subtypes: implications for treatment.
Next Document:  Prophylaxis in von Willebrand disease.